Abstract
Objective
To examine the long-term effectiveness of fluoroscopy-guided foam sclerotherapy for varicose veins in the legs.
Methods
This retrospective cohort study included consecutive patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs at the authors’ center during a period from August 1, 2011, to May 31, 2016. The last follow-up was conducted by a telephone/WeChat interactive interview in May 2022. Recurrence was defined as the presence of varicose veins regardless of symptoms.
Results
The final analysis included 94 patients (58.3 ± 7.8 years of age; 43 men; 119 legs). The median Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical class was 3.0 (interquartile range [IQR]: 3.0, 4.0). C5 and C6 accounted for 5.0% (6/119) of the legs. The average total amount of the foam sclerosant used during the procedure was 35 ± 12 mL (range: 10-75 mL). No patients developed stroke, deep vein thrombosis, or pulmonary embolism after the treatment. At the last follow-up, the median CEAP clinical class reduction was 3.0. All 119 legs except for class 5 achieved the CEAP clinical class reduction by at least one grade. The median venous clinical severity score was 2.0 (IQR: 1.0, 5.0) at the last follow-up vs 7.0 (IQR: 5.0, 8.0) at the baseline (P < .001). The recurrence rate was 30.9% (29/94) in the overall analysis, 26.6% (25/94) for the great saphenous vein and 4.3% (4/94) for the small saphenous vein (P < .001). Five patients received subsequent surgical treatment, and the remaining patients opted to receive conservative treatments. Among the two C5 legs at the baseline, ulcer recurred in one leg at 3 months after the treatment and healed after conservative treatments. In the four C6 legs at the baseline, ulcer healed within a month in all patients. The rate of hyperpigmentation was 11.8% (14/119).
Conclusions
Long-term outcomes in patients undergoing fluoroscopy-guided foam sclerotherapy are satisfying, with minimal short-term safety concerns.
Keywords: Foam sclerotherapy, Fluoroscopy, Varicose vein, Recurrence
Article Highlights.
-
•
Type of Research: Single-center, retrospective cohort study
-
•
Key Findings: This retrospective cohort study included 94 consecutive patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs (119 legs). No patient developed stroke, deep vein thrombosis, or pulmonary embolism. With the 8-year median follow-up (minimum of 6 years), the recurrence rate was 30.9%. The median Clinical-Etiology-Anatomy-Pathophysiology clinical class reduction was 3.0. All 119 legs except for class 5 achieved the Clinical-Etiology-Anatomy-Pathophysiology clinical class reduction by at least one grade.
-
•
Take Home Message: Long-term outcomes are satisfactory after fluoroscopy-guided foam sclerotherapy for varicose veins.
Ultrasound-guided foam sclerotherapy has been increasingly used to manage varicose veins in the legs, but with lower efficacy, both short-term and long-term, in comparison with conventional surgery and endovenous laser/radiofrequency ablation.1,2 We previously reported the use of foam sclerotherapy under fluoroscopy guidance in 35 patients (42 legs) with venous ulcers due to varicose veins.3 The 12-month ulcer healing rate was 100%, with the mean time to healing at 32 days. The rate of postprocedural superficial thrombophlebitis was 50%. None of the patients developed stroke, deep vein thrombosis, or pulmonary embolism. We have now completed a larger cohort study with long-term follow-up. Results are reported below.
Methods
Patient cohort
This is a retrospective cohort study of the patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs at Zhenjiang Municipal Hospital of Traditional Chinese Medicine (Zhenjiang, Jiangsu, China) between August 1, 2011, and May 31, 2016. The study protocol was approved by the institutional ethics committee (#201107). Patient consent was waived because of the retrospective nature of the study. The last follow-up was conducted in May 2022. Recurrence was defined as the presence of varicose veins regardless of symptoms.
Procedure
Indwelling needles (24-gauge) were placed every 10 to 20 cm in the varicose veins and secured in position using Tegaderm (3M). Patients were then placed in a supine position. Digital subtraction venography was used to verify the patency of the deep veins and iliac veins. Foam sclerosant was prepared by mixing l.0% polidocanol sclerosant (CN00006560; Shanxi Tianyu Pharmaceuticals) and air at a 1:4 ratio and injected under fluoroscopy, as described previously.3 A “filling defect technique” was used to monitor the advance of the foam sclerosant in blood vessels until the hypointense foam sclerosant completely replaced the contrast medium in the varicose veins or the foam was about to enter the perforator veins.4 For saphenous veins, manual pressing was routinely applied to the saphenofemoral and saphenopopliteal junctions. The maximum dose was 2 mg of polidocanol solution per kilogram of body weight. The maximum contrast agent was 75 mL per patient. All patients received postprocedure compression with elastic bandage for 24 hours and with compression stockings (30-40 mm Hg) for 2 months.
Statistical analysis
Continuous variables are shown as mean ± standard deviation if following the normal distribution and as median (interquartile range [IQR]) otherwise. Categorical variables are shown as number and percentage. The Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical class and venous clinical severity score (VCSS) were compared between the baseline and the last follow-up using Student’s t-test for paired samples. Multivariate Cox proportional hazards regression was used to identify the risk factors for recurrence. Age (cutoff at 60 years of age), sex, hypertension, diabetes, CEAP C classification, and VCSS before the treatment were included in the regression analysis as independent variables. Results of the regression analysis are shown as hazard ratio (HR) and 95% confidence interval (CI).
Results
A total of 130 patients (161 legs) underwent fluoroscopy-guided foam sclerotherapy at Zhenjiang Municipal Hospital of Traditional Chinese Medicine during a period from August 1, 2011, to May 31, 2016. Thirty-six patients were lost to the follow-up. The final analysis included 94 patients (58.3 ± 7.8 years of age; 43 men; 119 legs) (Table I). The rate of major comorbidities was 21.3% (20/94) for hypertension and 20.2% (19/94) for type 2 diabetes. The CEAP clinical class was C2 in 26 (21.9%), C3 in 38 (31.9%), C4 in 49 (41.2%), C5 in 2 (1.7%), and C6 in 4 (3.3%) legs. The median VCSS was 7.0 (IQR: 5.0, 8.0; range: 3-15). The treated incompetent veins were the great saphenous vein (GSV) in 80 legs (67.2%), the small saphenous vein (SSV) in 22 legs (18.5%), the GSV plus SSV in 11 legs (9.2%), and the GSV plus anterior accessory saphenous veins in 6 legs (5.1%).
Table I.
Demographic, baseline characteristics, and procedure information (94 patients; 119 legs)
| Variable | Value |
|---|---|
| Age, mean ± SD, years | 58.3 ± 7.8 |
| Male sex, No. (%) | 43 (45.7) |
| Comorbidities, No. (%) | |
| Diabetes | 19 (20.2) |
| Hypertension | 20 (21.3) |
| CEAP clinical class, No. (%) | |
| C2 | 26 (21.9) |
| C3 | 38 (31.9) |
| C4 | 49 (41.2) |
| C5 | 2 (1.7) |
| C6 | 4 (3.3) |
| Locations, No. (%) | |
| GSV | 80 (67.2) |
| GSV plus AASV | 6 (5.1) |
| SSV | 22 (18.5) |
| GSV plus SSV | 11 (9.2) |
| VCSS, median (IQR) | 7.0 (5.0, 8.0) |
| Injection sites, median (IQR) | 6.0 (5.0, 7.0) |
| Foam sclerosant, mean ± SD, mL | 35.6 ± 12.3 |
| Procedural time, mean ± SD, minutes | 42.3 ± 10.4 |
AASV, Anterior accessory saphenous veins; CEAP, Clinical-Etiology-Anatomy-Pathophysiology; GSV, great saphenous vein; IQR, interquartile range; SD, standard deviation; SSV, small saphenous vein; VCSS, venous clinical severity score.
The median number of sclerosant injection sites was 6.0 (IQR: 5.0, 7.0; range: 1-9) (Table I). The total amount of the foam sclerosant used during the procedure was 35.6 ± 12.3 mL (range: 10-75 mL). The average procedural duration was 42.3 ± 10.4 minutes (range: 25-70 minutes). No patients developed stroke, deep vein thrombosis, or pulmonary embolism after the treatment.
The median follow-up was 8.0 years (IQR: 7.0, 8.0; range: 6-10 years). At the last follow-up, the CEAP clinical class was C0 in 69 (58.0%), C1 in 8 (6.7%), C2 in 19 (16.0%), C3 in 13 (10.9%), C4 in 4 (3.4%), and C5 (5.0%) in 6 legs (Table II). All 119 legs except for the two class 5 legs at the baseline achieved the C classification reduction by at least one grade. The median C classification reduction was 3.0 (IQR: 3.0, 4.0; range: 0-6). The median VCSS was 2.0 (IQR: 1.0, 5.0) at the last follow-up vs 7.0 (IQR: 5.0, 8.0) at the baseline (P < .001). The recurrence rate was 30.9% (29/94) in the overall analysis, 26.6% (25/94) for the GSV and 4.3% (4/94) for the SSV (P < .001). Among the two C5 legs at the baseline, ulcer recurred in one leg at 3 months after the treatment and healed after conservative treatments. In the four C6 legs at the baseline, ulcer healed within a month in all patients. The rate of hyperpigmentation was 11.8% (14/119).
Table II.
Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification and venous clinical severity score (VCSS) at the baseline vs the last follow-up
| Baseline | Last follow-up | P value | |
|---|---|---|---|
| CEAP clinical class, No. (%) | <.001 | ||
| C0 | – | 69 (58.0) | |
| C1 | – | 8 (6.7) | |
| C2 | 26 (21.8) | 19 (16.0) | |
| C3 | 38 (31.9) | 13 (10.9) | |
| C4 | 49 (41.2) | 4 (3.4) | |
| C5 | 2 (1.7) | 6 (5.0) | |
| C6 | 4 (3.3) | 0 | |
| CEAP, median (IQR) | 3.0 (3.0, 4.0) | 0.0 (0.0, 2.0) | <.001 |
| VCSS, median (IQR) | 7.0 (5.0, 8.0) | 2.0 (1.0, 5.0) | <.001 |
C0, No visible or palpable signs of venous disease; C1, telangiectases, reticular veins; C2, varicose veins; C3, edema without skin changes; C4, changes in the skin and subcutaneous tissue; C5, healed ulcer; C6, active ulcer; IQR, interquartile range.
In the multivariate regression analysis, recurrence was not associated with any of the demographic or baseline characteristics, including older age (HR: 1.492, 95% CI: 0.674-3.299), the male sex (HR: 0.539, 95% CI: 0.237-1.224), hypertension (HR: 1.559, 95% CI: 0.641-3.792), diabetes (HR: 0.551, 95% CI: 0.201-1.510), higher CEAP C classification (HR: 0.999, 95% CI: 0.531-1.880), and higher VCSS (HR: 0.960, 95% CI: 0.738-1.250) before the treatment.
Discussion
The current study revealed satisfactory long-term outcomes in patients who underwent fluoroscopy-guided foam sclerotherapy for varicose veins in the legs. For all 119 legs except for class 5, the CEAP clinical class at the last follow-up was at least one grade lower than before the treatment. The median CEAP clinical class reduction was 3.0. The recurrence rate was 30.9%.
In a previous study of endovenous laser ablation for varicose veins, the 2-year and 5-year recurrence rate was 15.9% and 22.7%, respectively.5 The 2-year and 5-year recurrence rate after surgery was slightly higher at 36.2% and 35.3%, respectively.6 Considering the longer period of follow-up (minimum: 6 years; median: 8 years), the recurrence rate in the current study (30.9%) was encouraging.
Shadid et al7 reported 11.3% 2-year rate of clinical recurrence in 213 patients who underwent ultrasound-guided foam sclerotherapy. In a long-term prospective cohort study by Chapman-Smith and Browne,8 the 5-year clinical recurrence rate with ultrasound-guided foam sclerotherapy was 26%. The recurrence rate in the current study (30.9%) was in the same range despite much longer follow-up (minimum: 6 years; median: 8 years), as well as lower sclerosant concentration (1% vs 3%) and lower sclerosant:air ratio (1:4 vs 1:3).
A higher rate of recurrence in GSV vs SSV, as observed in the current study, is consistent with the previously reported association for a higher rate of recurrence after foam sclerotherapy with the larger diameter of the varicose veins.9 However, Hamahata et al10 reported no statistically significant differences in vascular diameter between the nonrecurrence and recurrence groups in their study. Such a discrepancy may be attributed to the use of the foam sclerosant with varying polidocanol concentration (1% vs 3%).
With advances in interventional radiology, angiography under fluoroscopy monitoring has become the “gold standard” in vessel assessment; fluoroscopy allows visualization of the varicose veins in more detail and with high resolution. In the current study, we were able to use a larger amount of the foam sclerosant (average of 35 mL; maximum of 75 mL) because fluoroscopy could monitor the spread of foam along all possible directions and avoid spillage into unintended blood vessels. In contrast, ultrasound imaging can track foam dissemination only along a single direction at one time and thus may not simultaneously detect foam entry in different directions into the other vessels or the deep vein system through perforating veins. The short-term safety of such a procedure is testified by the fact that no patient developed either stroke, pulmonary embolism, or deep vein thrombosis in the 130 patients in the current study, as well as the 35 patients who underwent the same procedure in a previous report.3
In a long-term study by Lam et al,11 both the CEAP clinical class and VCSS were significantly lower at 2 years after the treatment (either surgery or ultrasound-guided foam sclerotherapy). At 8 years after the treatment, however, neither the CEAP clinical class nor the VCSS differed from the pretreatment baseline. In a study by Memetoğlu et al,12 the VCSS at 22 months after ultrasound-guided foam sclerotherapy was 12 vs 14 in the baseline in patients with partial occlusion, but did not differ from the baseline in patients with complete occlusion (7 at both time points). In the current study, both the CEAP C classification and VCSS at the last follow-up were significantly lower than the pretreatment baseline. Indeed, all 119 legs except for the two C5 legs achieved the CEAP clinical class reduction by at least one grade. The rate of hyperpigmentation (11.8%) in the current study is at the lower end of the range (10%-30%) as reported in previous studies.13
The current study has several limitations. First, the follow-up was not routinely conducted. Second, fluoroscopy-guided foam sclerotherapy was not compared with any other treatment methods. The assessment of the effectiveness was based on historical data in the literature and thus subject to substantial bias. Third, both the physicians and patients were exposed to radiation. Vigilant protective measures must be carefully implemented.
In summary, fluoroscopy-guided foam sclerotherapy could achieve satisfying long-term outcomes with minimal safety concerns.
Author Contributions
Conception and design: YZ, DW
Analysis and interpretation: YZ, DW, KS, HZ
Data collection: JL, DS, JL
Writing the article: YZ
Critical revision of the article: YZ, DW, KS, HZ, JL, DS, JL
Final approval of the article: YZ, DW, KS, HZ, JL, DS, JL
Statistical analysis: Not applicable
Obtaining funding: YZ
Overall responsibility: YZ
Footnotes
This study was funded by 2021 Zhenjiang Science and Technology Innovation Funds (Key R&D Program—Social Development) Project (SH2021041).
Author conflict of interest: none.
The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
References
- 1.Rasmussen L., Lawaetz M., Bjoern L., Vennits B., Blemings A., Eklof B. Randomized trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011;98:1079–1087. doi: 10.1002/bjs.7555. [DOI] [PubMed] [Google Scholar]
- 2.Lawaetz M., Serup J., Lawaetz B., Bjoern L., Blemings A., Eklof B., et al. Comparison of endovenous ablation techniques, foam sclerotherapy and surgical stripping for great saphenous varicose veins: extended 5-year follow-up of a RCT. Int Angiol. 2017;36:281–288. doi: 10.23736/S0392-9590.17.03827-5. [DOI] [PubMed] [Google Scholar]
- 3.Zhu Y., Wu D., Sun D., Song K., Li J., Lin J. Ultrasound- and fluoroscopy-guided foam sclerotherapy for lower extremity venous ulcers. J Vasc Surg Venous Lymphat Disord. 2020;8:783–788. doi: 10.1016/j.jvsv.2019.11.006. [DOI] [PubMed] [Google Scholar]
- 4.Li L., Hong X.Y., Zeng X.Q., Luo P.L., Yi Q. Technical feasibility and early results of radiologically guided foam sclerotherapy for treatment of varicose veins. Dermatol Surg. 2011;37:992–998. doi: 10.1111/j.1524-4725.2011.02021.x. [DOI] [PubMed] [Google Scholar]
- 5.Nandhra S., El-sheikha J., Carradice D., Wallace T., Souroullas P., Samuel N. A randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins. J Vasc Surg. 2015;61:741–746. doi: 10.1016/j.jvs.2014.09.037. [DOI] [PubMed] [Google Scholar]
- 6.Rasmussen L., Lawaetz M., Bjoern L., Blemings A., Eklof B. Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years. J Vasc Surg. 2013;58:421–426. doi: 10.1016/j.jvs.2012.12.048. [DOI] [PubMed] [Google Scholar]
- 7.Shadid N., Ceulen R., Nelemans P., Dirksen C., Veraart J., Schurink G.W., et al. Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for the incompetent great saphenous vein. Br J Surg. 2012;99:1062–1070. doi: 10.1002/bjs.8781. [DOI] [PubMed] [Google Scholar]
- 8.Chapman-Smith P., Browne A. Prospective five-year study of ultrasound-guided foam sclerotherapy in the treatment of great saphenous vein reflux. Phlebology. 2009;24:183–188. doi: 10.1258/phleb.2009.008080. [DOI] [PubMed] [Google Scholar]
- 9.Myers K.A., Jolley D., Clough A., Kirwan J. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg. 2007;33:116–121. doi: 10.1016/j.ejvs.2006.09.005. [DOI] [PubMed] [Google Scholar]
- 10.Hamahata A., Yamaki T., Sakurai H. Outcomes of ultrasound-guided foam sclerotherapy for varicose veins of the lower extremities: a single center experience. Dermatol Surg. 2011;37:804–809. doi: 10.1111/j.1524-4725.2011.02003..x. [DOI] [PubMed] [Google Scholar]
- 11.Lam Y.L., Lawson J.A., Toonder I.M., Shadid N.H., Sommer A., Veenstra M., et al. Eight-year follow-up of a randomized clinical trial comparing ultrasound-guided foam sclerotherapy with surgical stripping of the great saphenous vein. Br J Surg. 2018;105:692–698. doi: 10.1002/bjs.10762. [DOI] [PubMed] [Google Scholar]
- 12.Memetoğlu M.E., Yılmaz M., Kehlibar T., Günay R., Ketenci B., Demirtaş M.M., et al. Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficience. J Vasc Surg Venous Lymphat Disord. 2020;8:799–804. doi: 10.1016/j.jvsv.2020.01.011. [DOI] [PubMed] [Google Scholar]
- 13.Gonzalez Ochoa A.J., Carrillo J., Manríquez D., Manrique F., Vazquez A.N. Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. J Vasc Surg Venous Lymphat Disord. 2021;9:154–162. doi: 10.1016/j.jvsv.2020.06.019. [DOI] [PubMed] [Google Scholar]
